Core Laboratories NV
🔔 Watch stock
Stock Watch
Stock Watch will tell you what changes at Core Laboratories NV.
Later $1 a month per stock — signing up is free, and you'll be the first to know when it launches.
Price history
Chart
Interactive price chart (TradingView).
52-week range: 9.90 $ to 19.70 $ · Last price: 11.40 $ (As of: September 17, 2026)
Key figures
Key figures at a glance
Every figure we hold for this stock, grouped by topic. The question mark next to a label explains what the number means.
Basics
Performance
Technical Indicators
Calculated from the price history · as of 09/18/2026
Valuation
Profitability
Balance Sheet & Safety
Growth
Dividend
Quality & Screener
Highlighted are things our editorial team noticed: green = stands out as strong, red = deserves a closer look. No single metric is a verdict on its own — always read it in context.
Comparison
Industry comparison
The stock alongside the largest companies in the same group. The median row is the middle value of the companies shown above — not of the whole industry.
Industry: Oil & Gas Equipment & Services
| Company | Market cap ($B) | P/E | EV/EBITDA | Gross Margin % | EBIT Margin % | Sales Growth (Year) % | Perf. 1Y % |
|---|---|---|---|---|---|---|---|
| Core Laboratories NV CLB | 0.5 | 18.4 | 11.4 | 19.5 | – | 0.5 | -8.4 |
| Schlumberger NV SLB | 77.5 | 22.2 | 13.2 | 17.0 | 12.3 | -1.6 | 53.4 |
| Baker Hughes Co BKR | 56.1 | 17.9 | 11.2 | 23.7 | 12.3 | -0.3 | 23.6 |
| Tenaris SA TS | 30.3 | 15.1 | 8.3 | 38.5 | 16.7 | -4.3 | 60.6 |
| TechnipFMC PLC FTI | 29.0 | 26.6 | 14.5 | 23.0 | 14.1 | 9.4 | 87.2 |
| Halliburton Company HAL | 28.5 | 18.0 | 9.8 | 15.1 | 12.6 | -3.3 | 57.0 |
| NOV Inc. NOV | 7.3 | 78.5 | 11.0 | 21.7 | 2.3 | -1.4 | 62.6 |
| Solaris Energy Infrastructure, Inc SEI | 6.8 | – | 23.5 | 49.9 | 25.8 | 98.7 | 109.9 |
| LandBridge Company LLC LB | 6.6 | 76.0 | 19.8 | 98.8 | 66.1 | 81.1 | 59.6 |
| Median of companies shown | 28.5 | 20.3 | 11.4 | 23.0 | 13.3 | -0.3 | 59.6 |
Based on the most recently reported figures. Only stocks from the same trading venue are lined up, so the market caps are counted in one currency. Compare in a chart →
Fiscal years
Annual Figures
Fiscal years from the audited annual reports, oldest first. EBIT is the operating profit before interest and taxes; total assets are everything the company owns.
Revenue, operating income and net income per fiscal year $M
Revenue Operating income Net income
| Fiscal Year | Revenue ($M) | EBIT ($M) | Net Income ($M) | EPS ($) | Operating Cash Flow ($M) | Equity ($M) | Total Assets ($M) |
|---|---|---|---|---|---|---|---|
| 2016 | 595 | 86 | 64 | 1.45 | 132 | 155 | 573 |
| 2017 | 660 | 112 | 83 | 1.88 | 124 | 149 | 585 |
| 2018 | 701 | 119 | 80 | 1.79 | 112 | 161 | 649 |
| 2019 | 668 | 97 | 102 | 2.28 | 90 | 178 | 775 |
| 2020 | 487 | -77 | -98 | -2.17 | 58 | 72 | 569 |
| 2021 | 470 | 45 | 20 | 0.42 | 37 | 156 | 581 |
| 2022 | 490 | 42 | 19 | 0.42 | 25 | 184 | 578 |
| 2023 | 510 | 55 | 37 | 0.77 | 25 | 225 | 586 |
| 2024 | 524 | 59 | 31 | 0.66 | 56 | 252 | 590 |
| 2025 | 527 | 50 | 30 | 0.64 | 37 | 266 | 584 |
Quarters
Quarterly Figures
Each bar is one quarter, the last one is the most recent. Use the switch to step through the individual figures.
Revenue & Profit
Cash Flow
Balance Sheet
Margins
Per Share
Click the chart or tab into it, then use ← and → to step through the periods.
None of the selected stocks reports this metric. Pick another metric or switch between annual and quarterly.
· Total · per year
These companies report in different currencies — switch on “Indexed” or pick a margin for a fair comparison.
The figures could not be loaded right now.
Source: fundamental data
| Quarter | EPS (Earnings Per Share) | EPS YoY (%) | Sales ($M) | Sales YoY (%) | Net Margin (%) | OCF ($M) | FCF ($M) |
|---|---|---|---|---|---|---|---|
| 2024: Q4 | 0.15 | 235.10 | 129 | 0.80 | 5.70 | 21 | 16 |
| 2025: Q1 | 0.00 | -104.90 | 124 | -4.70 | -0.10 | 7 | 3 |
| 2025: Q2 | 0.22 | 18.30 | 130 | -0.30 | 8.20 | 15 | 10 |
| 2025: Q3 | 0.30 | 23.10 | 135 | 0.10 | 10.60 | 9 | 6 |
| 2025: Q4 | 0.11 | -31.30 | 138 | 7.00 | 3.60 | 8 | 4 |
| 2026: Q1 | -0.02 | – | 122 | -1.40 | -0.60 | 4 | -1 |
| 2026: Q2 | 0.13 | -40.90 | 125 | -4.30 | 4.80 | 8 | 3 |
What Do These Terms Mean?
- EPS (Earnings Per Share):
- Quarterly profit divided by the total share count — how much of the profit works out to a single share.
- YoY (Year over Year):
- Change versus the same quarter a year ago — this is how you compare without seasonal distortion (e.g. the holiday shopping season).
- Sales:
- All revenue for the quarter, before any costs are deducted — the top line of the income statement.
- Net Margin:
- What percentage of sales is left over as profit in the end. Negative means the company is posting a loss.
- OCF (Operating Cash Flow):
- The cash that actually flows into the till from the core business during the quarter — harder to dress up than book profit.
- FCF (Free Cash Flow):
- Operating cash flow minus capital expenditures — the money that's genuinely free to use, say for paying down debt, buybacks, or dividends.
Screening
Appears in These Scanners
This stock currently matches 7 of our scanner strategies — each hit links to the scanner.
Quality & Balance Sheet
Risk & Weakness
- Below the 50- & 200-SMA
- Downward Momentum
- Stage 4 (Downtrend)
- Stan Weinstein: Stage 4
- Stan Weinstein: Stage 4B-
- Weakness Cluster
Only genuine hits from verified scanners count; pure ranking metrics (P/E, P/S, and similar, which just sort the whole universe) don't count as a hit. Scanners marked in red are red-flag signals (risk/short scanners) — appearing there is not a seal of approval. View all scanners
Outlook
Analysts & Price Target
Combined picture of the price targets and recommendations of every analyst covering the stock. Price targets are expectations for the next 12 months, not promises — and they often follow the price rather than predict it.
Distribution of Recommendations
Estimates by Fiscal Year
| Fiscal Year | EPS Estimate ($) | EPS Range ($) | Revenue Estimate ($M) | Expected Growth | Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 0.46 | 0.37 – 0.51 | 510 | -39.1% | 3 |
| 12/31/2027 | 0.70 | 0.58 – 0.79 | 535 | 54.0% | 3 |
Average of the analyst estimates for the coming fiscal years. The range shows how far the most optimistic and the most cautious estimate sit apart — the wider it is, the less certain the expectation.
Valuation
What is priced in?
Instead of guessing what the stock is worth, we turn the question around: what free cash flow growth has to happen for today’s market value to add up? The assumptions behind it can be moved.
Today’s market value implies roughly 20.0% growth in free cash flow per year over ten years (assumptions: discount rate 10.0%, terminal growth 2.5%).
| Free cash flow (last twelve months) | $10.7M |
|---|---|
| Market cap | $529.0M |
| Free cash flow in year ten | $66.5M |
| Terminal value as a share of market value | 66.2% |
For comparison: over the past five years free cash flow shrank by 13.5% per year.
It shows which assumption is built into today’s price, not whether that assumption will hold. Every assumption can be changed with the sliders; the figures move with them.
A simplified model calculation — not a forecast and not a recommendation.
AI classification
AI Rating
Not yet rated — we only show a category once an SEC-backed file with at least two cited passages is available.
Growth
Growth Score
Ten checks against the annual reports — each one passed counts a point.
- Revenue grows by more than 15% a year over three years 2.4%
- More than 10% revenue growth is expected for the coming year 5.2%
- Share count grows by less than 3% a year -0.2%
- Revenue growth plus cash-flow margin add up to at least 40 ("Rule of 40") 4.7%
- Gross margin at 40% or higher and without meaningful erosion 17.9%
- Goodwill from acquisitions does not grow faster than revenue 18.1%
- Net debt below twice EBITDA 2.0 x EBITDA
- Operating cash flow covers the profits of the last three years 20 m
- Return on capital at 15% or higher, or up versus two years ago 10.6%
- Insiders hold at least 10% or are net buyers 1.4%
A criterion without figures counts neither as passed nor as failed; a score is only produced from 7 judgeable criteria upwards. Source: fundamental data. All ten criteria in detail
Quality check
AAQS
2/10The AAQS (AlleAktien Quality Score) checks 10 quality criteria on growth, profitability, and balance-sheet strength — per the methodology developed and published by AlleAktien, calculated by us from our own fundamental data. A stock counts as a quality stock from 9 out of 10 points. Where a company has a shorter listing history, we calculate over the fiscal years available (at least five).
- Sales growth 10Y > 5% -1.3%
- Exp. sales growth 3Y > 5% 0.8%
- EBIT growth 10Y > 5% -5.8%
- Exp. EBIT growth 3Y > 5% 5.0%
- Net debt < 4x EBIT 2.8x
- EBIT positive, 10Y straight 9
- Max. EBIT decline < 50% 100.0%
- Return on equity > 15% 19.4%
- ROCE > 15% 10.6%
- Expected return > 10% 9.4%
View stocks with the full AAQS score · Read the methodology at AlleAktien
Source: fundamental data
Insiders
Insider Transactions
Reportable transactions by officers and major shareholders from SEC Form 4 filings. "Other" includes things like stock grants and option exercises without a buy/sell character.
| Date | Person | Role | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Aug 1, 2026 | Teo Sow Hang | CAO & Treasurer | Other | 200 | 0.00 | – |
| Aug 1, 2026 | Teo Sow Hang | CAO & Treasurer | Other | 90 | 10.64 | 958 |
| Aug 1, 2026 | Teo Sow Hang | CAO & Treasurer | Other | 240 | 0.00 | – |
| Aug 1, 2026 | Teo Sow Hang | CAO & Treasurer | Other | 108 | 10.64 | 1,149 |
| Aug 1, 2026 | Tattoli Mark Damian | SVP, Gen Counsel & Secretary | Other | 250 | 0.00 | – |
| Aug 1, 2026 | Tattoli Mark Damian | SVP, Gen Counsel & Secretary | Other | 99 | 10.64 | 1,053 |
| Jul 31, 2026 | Bruno Lawrence | Chairman and CEO | Buy | 5,000 | 10.78 | 53,900 |
The company
About the Company
Core Laboratories Inc. bietet Dienstleistungen und Produkte zur Reservoirbeschreibung und Produktionssteigerung für die Öl- und Gasindustrie in den USA und international an.
- Employees
- 3,300
- Headquarters
- Houston, TX
- Address
- 6316 Windfern Road, 77040 Houston, United States
- Phone
- 713 328 2673
- Website
- corelab.com
- IPO Date
- 09/20/1995
- ISIN
- US21867A1051
- Stock Split
- 2:1 on 07/09/2010
- Stock Split
- 2:1 on 12/22/1997
Management
| Name | Title | Birth Year |
|---|---|---|
| Lawrence V. Bruno | Chairman of the Board, CEO, President & COO | 1960 |
| Christopher Scott Hill | Senior VP & CFO | 1970 |
| Gwendolyn Y. Gresham M.B.A. | Senior Vice President of Corporate Development & Investor Relations | 1968 |
| Mark Damian Tattoli J.D. | Senior VP, Secretary & General Counsel | 1972 |
| Sow Hang Teo | VP, Treasurer & Chief Accounting Officer | 1970 |
| Leslie D. Linklater | Vice President of People, Organization & Culture | – |
Executives per the latest required filings; titles kept in their original language. Source: fundamental data.
Filings
Company Filings (8-K)
An 8-K is the filing a US company must use to disclose material events immediately — takeovers, changes at the top, major contracts or payment troubles, for instance. The links open the original document at the US Securities and Exchange Commission (SEC).
- 08/25/2026 Core Laboratories Inc. /DE/ (CLB): Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers; Financial Statements and Exhibits SEC ↗
- 07/29/2026 Core Laboratories Inc. /DE/ (CLB): Results of Operations and Financial Condition; Regulation FD Disclosure; Financial Statements and Exhibits SEC ↗
Data as of: September 17, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.